Acta Med. 2017, 60: 140-145
https://doi.org/10.14712/18059694.2018.9
Dose Dependent Prophylactic Efficacy of 6-Chlorotacrine in Soman-Poisoned Mice
References
1. J. Organophosphate/nerve agent poisoning: mechanism of action, diagnosis, prophylaxis and treatment. Adv Clin Chem 2004; 38: 151–216.
<https://doi.org/10.1016/S0065-2423(04)38006-6>
2. MB, Krstic DZ, Lazarevic-Pasti TD, Bondzic AM, Vasic VM. Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Curr Neuropharmacol 2013; 11: 315–335.
<https://doi.org/10.2174/1570159X11311030006>
<PubMed>
3. M, Prostran, M. Pyridinium oximes as cholinesterase reactivators. Structure-activity relationship and efficacy in the treatment of poisoning with organophosphorus compounds. Curr Med Chem 2009; 16: 2177–2188.
<https://doi.org/10.2174/092986709788612729>
4. , J. Review of oximes in the antidotal treatment of poisoning by organophosphorus nerve agents. J Toxicol Clin Toxicol 2002; 40: 803–816.
<https://doi.org/10.1081/CLT-120015840>
5. TM. Comparison of several oximes on reactivation of soman-induced blood, brain and tissue cholinesterase activity in rats. Arch Toxicol 1993; 67: 637–646.
<https://doi.org/10.1007/BF01974071>
6. DE, Kalasz H, Petroianu GA, Tekes K. Entry of oximes into the brain: A review. Curr Med Chem 2008; 15: 743–753.
<https://doi.org/10.2174/092986708783955563>
7. J, Zemek F, Bajgar J, et al. Partition of bispyridinium oximes (trimedoxime, K074) administered in therapeutic doses into different parts of the rat brain. J Pharm Biomed Anal 2011; 54: 1082–1087.
<https://doi.org/10.1016/j.jpba.2010.11.024>
8. J, Fusek J, Kassa J, Kuca K, Jun D. Chemical aspects of pharmacological prophylaxis against nerve agent poisoning. Curr Med Chem 2009; 16: 2977–2986.
<https://doi.org/10.2174/092986709788803088>
9. I, Krivoy A, Rotman E, Finkelstein A, Tashma Z, Yehezkelli Y. Pharmacologic prophylaxis against nerve agent poisoning. Isr Med Assoc J 2005; 7: 182–187.
10. J, Jun D, Bajgar J, Kuca K. Prophylaxis against nerve agent intoxication. Def Sci J 2006; 56: 775–784.
<https://doi.org/10.14429/dsj.56.1941>
11. B, Quigley MD, Kokla MA. Seven-day pyridostigmine administration and thermoregulation during rest and exercise in dry heat. Aviat Space Environ Med 1993; 64: 905–911.
12. TC. Organophosphate poisoning. Pharmacol Therap 1993; 58: 51–66.
<https://doi.org/10.1016/0163-7258(93)90066-M>
13. J, Vachek J. A comparison of the efficacy of pyridostigmine alone and the combination of pyridostigmine with anticholinergic drugs as pharmacological pretreatment of tabun-poisoned rats and mice. Toxicology 2002; 177: 179–185.
<https://doi.org/10.1016/S0300-483X(02)00219-6>
14. J, Koupilova M., Herink J, Vachek J. The long term influence of low-level sarin exposure on behavioral and neurophysiological functions in rat. Acta Medica (Hradec Králové) 2001; 44: 21–27.
15. J, Korabecny J, Nepovimova E. The evalution of benefit of newly prepared reversible inhibitors of acetylcholinesterase and commonly used pyridostigmine as pharmacological pretreatment of soman- poisoned mice. Acta Medica (Hradec Králové) 2017; 60: 37–43.
<https://doi.org/10.14712/18059694.2017.45>
16. Tallarida R, Murray R. Manual of Pharmacological Calculation with Computer Programs. New York: Springer-Verlag, 1987.
17. G, Verdelet T, Renou J, et al. Reactivators of acetylcholinesterase inhibited by organophosphorus nerve agents. Acc Chem Res 2012; 45: 756–766.
<https://doi.org/10.1021/ar2002864>
18. B, Stojiljkovic MP. Unequal efficacy of pyridinium oximes in acute organophosphate poisoning. Clin Med Res 2007; 5: 71–82.
<https://doi.org/10.3121/cmr.2007.701>
<PubMed>
19. TC, Rice P, Vale JA. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev 2006; 25: 297–323.
<https://doi.org/10.2165/00139709-200625040-00009>
20. DE, Hasan MY, Nurulain SM, Shafiullah M, Kuca K, Petroianu GA. Acetylcholinesterase inhibitors as pretreatment before acute exposure to organophosphates: assessment using methyl-paraoxon. CNS Neurol Dis Drug Targets 2012; 11: 1052–1060.
<https://doi.org/10.2174/1871527311211080016>
21. K, Kaliste-Korhonen E, Raushel FM, Hanninen O. Success of pyridostigmine, physostigmine, eptastigmine and phosphotriesterase treatments in acute sarin intoxication. Toxicology 1999; 134: 169–178.
<https://doi.org/10.1016/S0300-483X(99)00029-3>
22. M, Musilek K, Dolezal M, Gunn-Moore F, Kuca K. Structure- activity relationship of quaternary acetylcholinesterase inhibitors – outlook for early myasthenia gravis treatment. Curr Med Chem 2010; 17: 1810–1824.
<https://doi.org/10.2174/092986710791111198>
23. JR, Hurst CG, Dunn MA. Pyridostigmine used as a nerve agent pretreatment under wartime condition. JAMA 1991; 266: 693–695.
<https://doi.org/10.1001/jama.1991.03470050093029>
24. RK, Haigh JR, Garcia GE, Feaster SR, Riel MA, Lenz DE. Oral administration of pyridostigmine bromide and huperzine A protects human whole blood cholinesterases from ex vivo exposure to soman. Chem-Biol Interact 2005; 157: 239–246.
<https://doi.org/10.1016/j.cbi.2005.10.031>
25. J, Bajgar J, Merka V. Prophylaxe von Vergiftungen mit Nervenkampfstoffen (Ergebnisse einer klinischen Studie). Koord Sanitatsdienst 2006; 24: 48–53.
26. MB, Goldstein LB, Jones KH, et al. Locomotor and sensorimotor performance deficit in rats following exposure to pyridostigmine bromide, DEET, and permethrin, alone and in combination. Toxicol Sci 2001; 60: 305–314.
<https://doi.org/10.1093/toxsci/60.2.305>
27. T, Aas P. Pretreatment and prophylaxis against nerve agent poisoning: Are undesirable behavioral side effects unavoidable? Neurosci Biobehav Rev 2016; 71: 657–670.
<https://doi.org/10.1016/j.neubiorev.2016.10.017>
28. J, Musilek K, Koomlova M., Bajgar J. A comparison of the efficacy of newly developed reversible inhibitors of acetylcholinesterase with commonly used pyridostigmine as pharmacological pre-treatment of soman-poisoned mice. Bas Clin Pharmacol Toxicol 2012; 110: 322–326.
<https://doi.org/10.1111/j.1742-7843.2011.00808.x>
29. DE, Hasan MY, Nurulain SM, Shafiullah M, Kuca K, Petroianu GA. Pretreatment for acute exposure to diisopropylfluorophosphate: in vivo efficacy of various acetylcholinesterase inhibitors. J Appl Toxicol 2011; 31: 515–523.
<https://doi.org/10.1002/jat.1589>
30. GA, Hasan MY, Nurulain SM, Arafat K, Sheen R, Nagelkerke N. Comparison of two pre-exposure treatment regimens in acute organophosphate (paraoxon) poisoning in rats: tiapride vs pyridostigmine. Toxicol Appl Pharmacol 2007; 219: 235–240.
<https://doi.org/10.1016/j.taap.2006.09.002>
31. GA, Nurulain SM, Shafiullah M, Hasan MY, Kuca K, Lorke DE. Usefulness of administration of non-organophosphate cholinesterase inhibitors before acute exposure to organophosphates: assessment using paraoxon. J Appl Toxicol 2013; 33: 894–900.
<https://doi.org/10.1002/jat.2760>
32. M, Musilek K, Horova A, et al. Preparation, in vitro screening and molecular modelling of symmetrical bis-quinolinium cholinesterase inhibitors-implications for early Myasthenia gravis treatment. Bioorg Med Chem Lett 2011; 21: 505–509.
<https://doi.org/10.1016/j.bmcl.2011.02.047>
33. J, Musilek O, Holas O, et al. Synthesis and in vitro evaluation of N-(bromobut-3-en-7-yl)-7-methoxy-1,2,3,4-tetrahydroacridine-9-amine as a cholinesterase inhibitor with regard to Alzheimer’s disease treatment. Molecules 2010; 15: 8804–12.
<https://doi.org/10.3390/molecules15128804>
<PubMed>
34. K, Korabecny J, Kral J, et al. 7-methoxy-tacrine-adamantylamine heterodimers as cholinesterase inhibitors in Alzheimer’s disease treatment – synthesis, biological evaluation and molecular modeling studies. Molecules 2013; 18: 2397–2418.
<https://doi.org/10.3390/molecules18022397>
<PubMed>
35. KL, Powchik P. Tacrine. Lancet 1995; 345: 625–630.
<https://doi.org/10.1016/S0140-6736(95)90526-X>
36. M, Cavalli A, Belluti F, et al. SAR of 9-amino-1,2,3,4-tetrahydroacridine-based acetycholinesterase inhibitors: synthesis, enzyme inhibitory activity, QSAR and structure-based CoMFA of tacrine analogues. J Med Chem 2000; 43: 2007–2018.
<https://doi.org/10.1021/jm990971t>
37. E, Korabecny J, Dolezal R, et al. Tacrine-trolox hybrids: A novel class of centrally active, nonhepatotoxic multi-target-directed ligands exerting anticholinesterase and antioxidant activities with low in vivo toxicity. J Med Chem 2015; 58: 8985–9003.
<https://doi.org/10.1021/acs.jmedchem.5b01325>
